Bexxar Corixa Corporation - Treatment for Non-Hodgkin’s Lymphoma

Bexxar is a dual-action therapy that combines the tumor-targeting ability of a cytotoxic monoclonal antibody and the therapeutic potential of radiation. Bexxar is indicated for the treatment of Non-Hodgkin’s lymphoma.

Posted: June 2003

View comments

Hide
(web1)